MedVellum
MedVellum
Back to Library

Empyema

On This Page

Overview

Empyema

Quick Reference

Critical Alerts

  • Empyema is a surgical infection - drainage is essential, not just antibiotics
  • Delay in drainage worsens outcomes - early intervention improves survival
  • Complicated parapneumonic effusion progresses to empyema without intervention
  • Loculated effusions require specialty intervention (VATS, fibrinolytics)
  • Consider empyema in any patient with pneumonia not responding to antibiotics

Key Diagnostics

  • CT chest with contrast (best for loculations, staging)
  • Diagnostic thoracentesis with pleural fluid analysis
  • Pleural fluid criteria: pH <7.2, glucose <40 mg/dL, LDH >1000 IU/L, positive Gram stain/culture
  • Blood cultures (often negative)
  • Inflammatory markers (CRP, procalcitonin)

Emergency Treatments

  • IV antibiotics: Empiric broad-spectrum coverage including anaerobes
  • Chest tube drainage: Large bore (24-28 Fr) or image-guided small bore
  • Cardiothoracic surgery consultation: For loculated disease, treatment failure
  • Intrapleural fibrinolytics: TPA/DNase for loculated empyema
  • Supportive care: Oxygen, fluids, nutrition

Definition

Empyema thoracis is defined as the presence of pus in the pleural space. It represents the end stage of a spectrum of pleural space infections that begins with simple parapneumonic effusion and progresses through complicated parapneumonic effusion to frank empyema. Early recognition and aggressive management are crucial for optimal outcomes.

Stages of Pleural Infection

StageDurationCharacteristicsDrainage
ExudativeDays 1-3Free-flowing, sterile, low LDHUsually resolves with antibiotics
FibrinopurulentDays 4-14Fibrin deposition, loculations, bacteria presentDrainage required
OrganizingDays 14+Pleural peel, trapped lungMay need decortication

Classification

Simple Parapneumonic Effusion

  • Sterile
  • pH >7.2
  • Glucose >60 mg/dL
  • LDH <1000 IU/L
  • Resolves with antibiotics alone

Complicated Parapneumonic Effusion

  • pH <7.2 or
  • Glucose <40 mg/dL or
  • LDH >1000 IU/L or
  • Positive Gram stain/culture
  • Requires drainage

Empyema

  • Frank pus in pleural space or
  • Positive culture with biochemical markers

Epidemiology

  • Incidence: 1-5% of patients hospitalized with pneumonia
  • Mortality: 5-15% with treatment; higher in elderly, immunocompromised
  • Risk factors: Diabetes, alcohol use, aspiration, poor dentition, immunosuppression
  • Trends: Increasing incidence of methicillin-resistant Staph aureus (MRSA)

Pathophysiology

Development of Empyema

Parapneumonic Route (Most Common)

  1. Pneumonia with adjacent pleural inflammation
  2. Increased capillary permeability → exudative effusion
  3. Bacterial invasion of pleural space
  4. Neutrophil influx, fibrin deposition
  5. Loculation formation
  6. Pus accumulation (empyema)
  7. Fibroblast proliferation → pleural peel

Other Routes

  • Direct extension from subdiaphragmatic infection
  • Esophageal perforation
  • Chest trauma or surgery
  • Hematogenous seeding (rare)

Microbiology

Community-Acquired

OrganismFrequencyNotes
Streptococcus pneumoniae40-50%Most common in community
Oral anaerobes20-30%Aspiration, poor dentition
Streptococcus milleri group15-25%Propensity for abscess
Staphylococcus aureus10-15%Including MRSA
Gram-negatives5-10%Klebsiella, E. coli

Hospital-Acquired/Post-Procedural

  • Staphylococcus aureus (including MRSA)
  • Gram-negative bacilli (Pseudomonas, Enterobacteriaceae)
  • Polymicrobial (especially post-operative)

Special Populations

  • Aspiration: Anaerobes predominate
  • Immunocompromised: Fungi, mycobacteria, Nocardia
  • IV drug use: S. aureus

Clinical Presentation

Symptoms

SymptomFrequencyDescription
Fever80-90%Often persistent despite antibiotics
Cough70-80%May be productive or dry
Pleuritic chest pain60-70%Sharp, worse with breathing
Dyspnea50-70%Proportional to effusion size
Weight lossCommonEspecially in chronic
Night sweatsCommonSuggest ongoing infection
Malaise/fatigueVery common

Signs

General

Chest Examination

FindingSignificance
Decreased breath soundsEffusion
Dullness to percussionFluid-filled pleural space
Reduced chest expansionSplinting, effusion
Pleural friction rubMay precede effusion
Bronchial breathingAbove effusion level

Clinical Scenarios

Typical Presentation

Subacute/Chronic Presentation

Acute Presentation


Fever
Common presentation.
Tachycardia
Common presentation.
Tachypnea
Common presentation.
Signs of sepsis (if advanced)
Common presentation.
Red Flags (Life-Threatening)

Critical Findings

Red FlagConcernAction
Signs of sepsis/septic shockSevere infectionSepsis protocol, urgent drainage
Respiratory distressLarge effusion, respiratory failureUrgent drainage, consider ICU
Tension physiologyLarge effusion with mediastinal shiftEmergent drainage
Air-fluid level (lung abscess rupture)Bronchopleural fistulaSurgical consultation
Bilateral empyemaSevere/disseminated infectionICU admission
Immunocompromised hostAtypical organisms, poor outcomeBroad coverage, early intervention

Indicators of Poor Prognosis

  • Age >65 years
  • Nosocomial acquisition
  • Poor nutritional status
  • Delayed drainage (>7 days from diagnosis)
  • Loculated disease
  • Positive blood cultures
  • Renal impairment
  • Low serum albumin

Differential Diagnosis

Causes of Exudative Pleural Effusion

ConditionDistinguishing Features
Simple parapneumonicpH >.2, resolves with antibiotics
Complicated parapneumonicpH <7.2, needs drainage
EmpyemaFrank pus, positive culture
Malignant effusionCytology positive, bloody, no response to antibiotics
Tuberculous effusionLymphocytic, elevated ADA, AFB stain/culture
Rheumatoid effusionVery low glucose, high LDH
ChylothoraxMilky, high triglycerides
HemothoraxBloody, hematocrit >0% of serum

Distinguishing Empyema from Other Effusions

Light's Criteria (Exudate if ANY met)

  1. Pleural protein / Serum protein >0.5
  2. Pleural LDH / Serum LDH >0.6
  3. Pleural LDH > 2/3 upper limit of serum normal

Empyema-Specific Criteria

  • pH <7.2
  • Glucose <40 mg/dL
  • LDH >1000 IU/L
  • Positive Gram stain or culture
  • Frank pus

Diagnostic Approach

Clinical Assessment

Key History

  • Duration and progression of symptoms
  • Prior pneumonia and antibiotic treatment
  • Risk factors for aspiration
  • Prior chest procedures or thoracic surgery
  • Dental health (anaerobic source)

Imaging

Chest X-ray

  • May show pleural effusion (blunted costophrenic angle)
  • Loculated effusions may appear as D-shaped densities
  • May see consolidation suggesting underlying pneumonia
  • Air-fluid level suggests bronchopleural fistula

CT Chest with Contrast (Gold Standard)

FindingInterpretation
Pleural enhancement (split pleura sign)Active pleural infection
LoculationsComplicated effusion
Air bubbles in fluidBronchopleural fistula or gas-forming organisms
Thickened pleuraOrganizing stage
Underlying consolidationPneumonia source
Mediastinal shiftLarge effusion

Ultrasound

  • Excellent for guiding thoracentesis
  • Can detect loculations and septations
  • "Complex" appearance suggests complicated effusion
  • Useful for small effusions

Thoracentesis

Indications

  • Any new pleural effusion in setting of pneumonia
  • Effusion >10mm on lateral decubitus or >25mm on CT

Fluid Analysis

TestEmpyema Finding
AppearancePurulent, turbid
pH<7.2
Glucose<40 mg/dL
LDH>000 IU/L
Protein> g/dL
Cell countPredominantly neutrophils
Gram stainMay be positive
CultureMay be positive (50-60%)

Laboratory Studies

TestPurpose
Blood culturesIdentify causative organism (positive ~20%)
CBCLeukocytosis, anemia of chronic disease
CRP/ESRInflammatory markers for monitoring
ProcalcitoninBacterial infection marker
LFTs, renal functionBaseline for antibiotic dosing
AlbuminNutritional status, prognosis

Treatment

Antibiotic Therapy

Empiric Regimens

SettingRegimenDuration
Community-acquiredCeftriaxone 2g IV + Metronidazole 500mg IV q8h2-4 weeks
AlternativeAmpicillin-sulbactam 3g IV q6h2-4 weeks
MRSA riskAdd Vancomycin 15-20mg/kg IV q8-12h2-4 weeks
Hospital-acquiredPiperacillin-tazobactam 4.5g IV q6h + Vancomycin2-4 weeks
Severe/ICUMeropenem 1g IV q8h + Vancomycin2-4 weeks

Duration

  • Minimum 2-3 weeks IV therapy
  • Consider PO step-down after clinical improvement and adequate drainage
  • Total treatment often 4-6 weeks

Pleural Space Drainage

Indications for Drainage (Any of)

  • Frank pus on thoracentesis
  • pH <7.2
  • Glucose <40 mg/dL
  • Positive Gram stain or culture
  • Loculated effusion on imaging

Drainage Options

MethodIndicationConsiderations
Small-bore catheter (12-14 Fr)Free-flowing effusion, early diseaseImage-guided placement
Large-bore chest tube (24-28 Fr)Thick pus, traditional approachMay drain better in thick fluid
Intrapleural fibrinolyticsLoculated effusionTPA 10mg + DNase 5mg BID x 3 days
VATS debridementFailed drainage, thick septationsFirst-line surgical option
Thoracotomy/DecorticationOrganizing stage, trapped lungMajor surgery, selected patients

Chest Tube Management

  • Place to 20 cmH2O suction
  • Monitor output (expect high initially)
  • Daily CXR to assess resolution
  • Flush if blocked (10-20mL saline)
  • Remove when output <100-150 mL/day and lung expanded

Intrapleural Fibrinolysis (MIST2 Trial Protocol)

Alteplase (TPA) 10 mg in 30 mL NS +
Dornase alpha (DNase) 5 mg in 30 mL NS

Administration:
- Dose TPA via chest tube, clamp 1 hour
- Then dose DNase, clamp 1 hour
- Then open to suction
- Repeat BID for 3 days (6 doses of each)

Evidence: Reduces hospital stay, need for surgery

Surgical Intervention

Indications for Surgery

  • Failed chest tube drainage after 5-7 days
  • Multiple loculations not responding to fibrinolytics
  • Thick pleural peel (organizing stage)
  • Necrotizing pneumonia with bronchopleural fistula
  • Underlying malignancy requiring diagnosis

Surgical Options

ProcedureDescription
VATS debridement/decorticationMinimally invasive, effective in fibrinopurulent stage
Open thoracotomy/decorticationFor thick peel, failed VATS
Open window thoracostomyFor failed decortication, chronically ill patients

Disposition

ICU Admission Criteria

  • Sepsis or septic shock
  • Respiratory failure requiring high-flow O2 or ventilation
  • Need for emergent drainage
  • Hemodynamic instability
  • Significant comorbidities requiring monitoring

Hospital Ward Admission

  • All patients with empyema require admission
  • Hemodynamically stable patients
  • Post-chest tube placement observation
  • IV antibiotic therapy

Transfer Considerations

  • Transfer to facility with cardiothoracic surgery if unavailable
  • Complex/refractory cases may need specialized center

Discharge Criteria

  • Afebrile for 48+ hours
  • Chest tube removed, lung expanded on CXR
  • Tolerating oral antibiotics
  • Stable or improving inflammatory markers
  • Follow-up arranged

Outpatient Follow-up

TimeframePurpose
1-2 weeksClinical assessment, labs, CXR
4-6 weeksCXR to confirm resolution
3 monthsFinal assessment, CT if concern for residual

Patient Education

Understanding Empyema

  • Empyema is an infection in the space around the lung
  • It usually develops from pneumonia
  • Treatment requires both antibiotics and drainage
  • Recovery takes several weeks

Chest Tube Care

  • The tube drains infected fluid from your chest
  • It will be attached to a collection device
  • Report pain, difficulty breathing, or tube dislodgement
  • Keep insertion site clean and dry

Recovery Expectations

  • Hospital stay typically 1-2 weeks or longer
  • Fatigue may persist for weeks to months
  • Gradual return to normal activity
  • Complete antibiotic course is essential

Warning Signs After Discharge

  • Fever returning
  • Worsening shortness of breath
  • Increasing chest pain
  • Drainage from chest tube site
  • Feeling unwell/deteriorating

Special Populations

Immunocompromised Patients

  • Higher risk for atypical organisms (fungi, mycobacteria, Nocardia)
  • May present with minimal symptoms
  • Broader empiric coverage needed
  • Consider early surgical consultation

Elderly Patients

  • Higher mortality rates
  • Often delayed presentation
  • More comorbidities complicating management
  • May require extended hospitalization

Post-Surgical/Traumatic Empyema

  • Often S. aureus or Gram-negatives
  • May have resistant organisms
  • Early surgical involvement
  • Consider possibility of esophageal injury

Tuberculous Empyema

  • Chronic presentation (weeks to months)
  • Lymphocytic predominant fluid
  • Elevated adenosine deaminase (ADA)
  • Requires anti-tuberculous therapy
  • May need surgical decortication

Pediatric Considerations

  • S. pneumoniae and S. aureus most common
  • More likely to develop empyema from CAP than adults
  • Often respond well to fibrinolytics
  • Generally better outcomes than adults

Quality Metrics

Performance Indicators

MetricTarget
CT imaging for suspected empyema>0%
Thoracentesis performed if indicated>5%
Drainage initiated within 24h of diagnosis>0%
Appropriate empiric antibiotics>5%
Cardiothoracic surgery consultation for drainage failure100%

Documentation Requirements

  • Pleural fluid analysis results
  • Imaging findings (loculations, size)
  • Drainage method and output
  • Antibiotic regimen and duration plan
  • Response to treatment
  • Disposition rationale

Key Clinical Pearls

Diagnostic Pearls

  1. Suspect empyema in any pneumonia not improving on antibiotics
  2. CT is gold standard for assessing loculations and guiding intervention
  3. pH <7.2 requires drainage - don't wait for culture
  4. Split pleura sign on contrast CT indicates active pleural infection
  5. Think of anaerobes in aspiration-related cases

Treatment Pearls

  1. Antibiotics alone are insufficient - drainage is essential
  2. Earlier drainage = better outcomes
  3. Small bore catheters work if free-flowing
  4. TPA/DNase combination reduces surgery need in loculated disease
  5. Don't delay surgery if drainage fails after 5-7 days

Disposition Pearls

  1. All empyema requires admission - no outpatient management
  2. CT before discharge is not always needed if clinically resolved
  3. Oral step-down after at least 1 week IV and clinical improvement
  4. Follow-up CXR at 4-6 weeks to confirm resolution
  5. Smoking cessation counseling for all

References
  1. Davies HE, et al. Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65 Suppl 2:ii41-53.
  2. Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection (MIST2 trial). N Engl J Med. 2011;365(6):518-526.
  3. Shen KR, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153(6):e129-e146.
  4. Colice GL, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest. 2000;118(4):1158-1171.
  5. Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174(7):817-823.

Version History
VersionDateChanges
1.02025-01-15Initial comprehensive version with 14-section template

At a Glance

EvidenceStandard
Last UpdatedRecently

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines